The Thread Connecting Space Rockets, Fake News and Artificial Intelligence
All three domains experience a technological book, said Yonatan Adiri, the CEO of Israeli medical startup
16:4131.05.18
According to Jonathan Adiri, founder and CEO of Israeli medical startup Healthy.io, there’s a thread connecting space rockets, fake news, and artificial intelligence: all are experiencing a technological boom, which has made them more advanced, and more affordable, than ever before, Mr. Adiri said. “We have reached an era in which the tech boom has caused a dramatic decline in costs,” he said.
Jonathan Adiri. Photo: Amit Sha'al
Healthy.io’s technology transforms regular smartphones into devices that perform medical urine analysis using computer vision algorithms, artificial intelligence, and the smartphones’ built-in camera. Using Healthy.io’s app, users can test for infections, chronic illnesses, and pregnancy-related complications. The company was founded in 2013 and is based in Tel Aviv.
For daily updates, subscribe to our newsletter by clicking here.
Mr. Adiri spoke on Tuesday to young entrepreneurs at an event hosted in Tel Aviv by Calcalist and Psagot Investment House Ltd. A former chief technology officer for late Israeli President Shimon Peres, in 2012, Mr. Adiri was nominated as a "Young Global Leader" by the World Economic Forum.
Jonathan Adiri. Photo: Amit Sha'al Mr. Adiri discussed China’s heavy investment in artificial intelligence technologies. Facial recognition technologies are slowly replacing I.D.s in China, among a variety of other uses, Mr. Adiri said.
Related stories:
- Healthy.io Brings Smartphone Urine Tests to U.S. Homes
- Startup Says It Is First to Copy Spider’s Silk Spinning Process
- AI Neuro-Disorder Detection and Treatment Startup BrainQ Technologies Raises $8.8 Million
In April, Healthy.io announced it has partnered with the American National Kidney Foundation and Pennsylvania-based Geisinger Health System to offer its smartphone-based urine tests at home. The three launched a clinical trial that month to test the technology among Geisinger’s patients.
